346 related articles for article (PubMed ID: 21325298)
21. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
22. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
[TBL] [Abstract][Full Text] [Related]
23. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
24. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.
Jenkinson C; Elliott V; Menon U; Apostolidou S; Fourkala OE; Gentry-Maharaj A; Pereira SP; Jacobs I; Cox TF; Greenhalf W; Timms JF; Sutton R; Neoptolemos JP; Costello E
J Proteomics; 2015 Jan; 113():400-2. PubMed ID: 25316052
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
26. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
[TBL] [Abstract][Full Text] [Related]
27. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract][Full Text] [Related]
28. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
29. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.
Yang Z; LaRiviere MJ; Ko J; Till JE; Christensen T; Yee SS; Black TA; Tien K; Lin A; Shen H; Bhagwat N; Herman D; Adallah A; O'Hara MH; Vollmer CM; Katona BW; Stanger BZ; Issadore D; Carpenter EL
Clin Cancer Res; 2020 Jul; 26(13):3248-3258. PubMed ID: 32299821
[TBL] [Abstract][Full Text] [Related]
30. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
31. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.
Jang SI; Lee HK; Chang EJ; Kim S; Kim SY; Hong IY; Kim JK; Lee HS; Yang J; Cho JH; Lee DK
Cancer Immunol Immunother; 2023 Aug; 72(8):2757-2768. PubMed ID: 37165046
[TBL] [Abstract][Full Text] [Related]
32. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
33. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.
Xu C; Jun E; Okugawa Y; Toiyama Y; Borazanci E; Bolton J; Taketomi A; Kim SC; Shang D; Von Hoff D; Zhang G; Goel A
Gastroenterology; 2024 Jan; 166(1):178-190.e16. PubMed ID: 37839499
[TBL] [Abstract][Full Text] [Related]
34. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
Cancer Sci; 2011 Sep; 102(9):1673-9. PubMed ID: 21615621
[TBL] [Abstract][Full Text] [Related]
36. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
Yako YY; Kruger D; Smith M; Brand M
PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
[TBL] [Abstract][Full Text] [Related]
37. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.
Jenkinson C; Elliott VL; Evans A; Oldfield L; Jenkins RE; O'Brien DP; Apostolidou S; Gentry-Maharaj A; Fourkala EO; Jacobs IJ; Menon U; Cox T; Campbell F; Pereira SP; Tuveson DA; Park BK; Greenhalf W; Sutton R; Timms JF; Neoptolemos JP; Costello E
Clin Cancer Res; 2016 Apr; 22(7):1734-1743. PubMed ID: 26573598
[TBL] [Abstract][Full Text] [Related]
38. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
39. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
Fahrmann JF; Bantis LE; Capello M; Scelo G; Dennison JB; Patel N; Murage E; Vykoukal J; Kundnani DL; Foretova L; Fabianova E; Holcatova I; Janout V; Feng Z; Yip-Schneider M; Zhang J; Brand R; Taguchi A; Maitra A; Brennan P; Max Schmidt C; Hanash S
J Natl Cancer Inst; 2019 Apr; 111(4):372-379. PubMed ID: 30137376
[TBL] [Abstract][Full Text] [Related]
40. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
